Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-06-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于控股子公司收到化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (859 characters) from Jinling Pharmaceutical Co., Ltd. regarding the approval notice received by its subsidiary for the listing of a chemical raw material drug. It includes details about the drug, approval, and impact on the company. There are no financial statements, no detailed financial data, or comprehensive report content. The document is an official announcement about a regulatory approval event, not a financial report or detailed management discussion. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-06-28 Chinese
金陵药业股份有限公司关于合作研发“间苯三酚原料药和口崩片”项目暨关联交易的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of a cooperative R&D project and related party transactions. It includes details about board approval, cooperation agreements, project delays due to regulatory announcements, and risk warnings to investors. The document is short (877 characters) and focuses on an update about a specific transaction and project progress rather than financial results or detailed financial data. It does not contain financial statements, earnings data, or comprehensive report content. It is not a report publication announcement since it provides substantive update information. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a related party transaction and project progress update that does not fit other specific categories like Capital/Financing Update or M&A Activity.
2024-06-27 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details amounts, dates, investment products, risk control measures, and impact on operations. The document is a regulatory announcement about the company's use of idle raised funds for cash management, including updates on investment products and risk controls. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is not a certification, call transcript, or management report. The document is a progress announcement related to capital management activities, specifically the use of idle raised funds for cash management, which fits best under Capital/Financing Update (CAP). The document length is about 5,429 characters, which is sufficient for a substantive announcement rather than a brief report publication notice or regulatory filing fallback. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2024-06-27 Chinese
金陵药业股份有限公司关于公司非职工监事辞职的公告
Board/Management Information Classification · 95% confidence The document is a short announcement regarding the resignation of a non-employee supervisor (监事) from the company's supervisory board. It includes details about the resignation, legal compliance, and the impact on the supervisory board's functioning. There is no financial data, no mention of financial results, no report attached or referenced, and no discussion of management or board changes beyond this resignation. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is short and focused solely on this personnel change, confirming it is not a full report or other filing type.
2024-06-20 Chinese
金陵药业股份有限公司关于全资子公司增资完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a capital increase and the related business registration change for a wholly-owned subsidiary of the company. It references prior approvals by the board and shareholders and provides details about the subsidiary's updated registration information. The document is short (922 characters) and serves as a formal notice of a corporate action rather than a detailed financial report or analysis. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report itself but an announcement of a corporate event related to capital increase and registration change. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-06-12 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the use of idle raised funds for cash management by Jinling Pharmaceutical Co., Ltd. It details the opening of a dedicated settlement account, the progress of cash management investments, risk control measures, and the impact on company operations. It references prior approvals by the board and shareholders' meeting and provides detailed tables of investment products and amounts. The document is relatively short (2993 characters) and serves as an update on the use of funds rather than a full financial report or audit. It does not contain financial statements or comprehensive financial analysis. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to the company's financing activities and management of raised funds.
2024-06-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.